We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00829088
First Posted: January 26, 2009
Last Update Posted: February 25, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.

Condition Intervention Phase
Pain Drug: AZD2066 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: An Open Label, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD2066 to Healthy Male Subjects

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Excretion (rate and extent) of radioactivity in urine and faeces following oral administration of [14C]AZD2066 [ Time Frame: Until >90% of predicted total radioactivity has been recovered ]
  • Pharmacokinetics of total radioactivity in plasma and unchanged AZD2066 in plasma [ Time Frame: Sampling at defined timepoints during residential period from pre-dose until 168h post-dose. ]
  • Metabolite profile in plasma and excreta [ Time Frame: Sampling at defined timepoints during residential period from pre-dose until 48h post-dose. ]

Secondary Outcome Measures:
  • AZD2066 metabolites in plasma+excreta if feasable [ Time Frame: Sampling at defined timepoints during residential period from pre-dose until 48h post-dose. ]
  • Safety and tolerability of AZD2066 by assessment of vital signs, laboratory variables, ECG and adverse events [ Time Frame: Assessments taken at visit 1 (enrolment), defined time points pre dose and post dose during visit 2 (residential period) and follow up visit 3. ]

Enrollment: 6
Study Start Date: January 2009
Study Completion Date: February 2009
Intervention Details:
    Drug: AZD2066
    1 dose oral solution
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provision of signed informed consent
  • Clinically normal physical findings and laboratory values as judged by the investigator and a normal resting ECG.

Exclusion Criteria:

  • History of somatic disease/condition, which may interfere with the objectives of the study.
  • History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder.
  • Healthy volunteers who have been exposed to radiation levels above background (eg, through X-ray examinations).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00829088


Locations
United Kingdom
Research Site
Cheshire, United Kingdom
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Emeline Ramos, MD AstraZeneca R&D, CPU Alderley Park, UK
Study Chair: Lars Ståhle, MD AstraZeneca R&D, Södertälje, Sweden
  More Information

Responsible Party: Rolf Karlsten, MD, PhD, Medical Science Director, Emerging Analgesia, Neuroscience, AstraZeneca R&D Södertälje, Sweden
ClinicalTrials.gov Identifier: NCT00829088     History of Changes
Other Study ID Numbers: D0475C00008
EudractCT No: 2008-006129-14
First Submitted: January 23, 2009
First Posted: January 26, 2009
Last Update Posted: February 25, 2009
Last Verified: February 2009

Keywords provided by AstraZeneca:
Mass balance
AZD2066
Pain
Pain conditions